CD8A and diffuse large B-cell lymphoma: Next, both subpopulations were compared before (baseline), during (Cycle 3) and after treatment (EOI) in R/R DLBCL patients, finding that the levels of CD8- NKs were significantly higher than CD8+ NKs levels at all sampling stages (Figure 1B).